Wyeth confirms importance of Xyntha for haemophilia A

Wyeth has confirmed the importance of Xyntha, its recombinant factor VIII product indicated for patients with haemophilia A.

Robert R Ruffolo, president of Wyeth Research and senior vice-president of Wyeth, stated that the drug established “a new standard in recombinant factor VIII product purification technology”.

His comments arrive as the US Food and Drug Administration (FDA) approved the product for both the control and prevention of bleeding episodes and surgical prophylaxis.

Xyntha is manufactured using a completely albumin-free process and state-of-the-art nanofiltration purification technology, according to Wyeth.

The company also highlights that Xyntha is the only recombinant factor VIII product to use an entirely synthetic purification process in its manufacture.

Previous clinical trials demonstrated a positive safety and efficacy profile for the drug in the prevention and control of bleeding episodes and for surgical prophylaxis for patients with haemophilia A.

“This is another example of Wyeth’s continued commitment to the advancement of science in the treatment of haemophilia,” Mr Ruffolo confirmed.

Wyeth Consumer Healthcare welcomed a new head of global research and development this week with the appointment of Isma Benattia.